Sarepta Therapeuticsの空売り状況は、投資家がSarepta Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Sarepta Therapeutics (NASDAQ:SRPT) 株価情報, 空売り情報

SAREPTA THERAPEUTICS INC

Sarepta Therapeutics

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics Inc

The Food and Drug Administration (FDA) on Tuesday said it is investigating the risk of acute liver failure with serious outcomes, including hospitalization and death, following Sarepta Therapeutics, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) Elevidys treatment and evaluating the need for further regulatory action.
Since approval, the agency has <a target="_blank" href="https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-deaths-due-acute-liver-failure-non-ambulatory-duchenne-muscular-dystrophy-patients" rel="noreferrer noopener">received</a> two reports of fatal acute liver failure following treatment of non-ambulatory pediatric male patients with Duchenne Muscular Dystrophy (DMD) with Elevidys (delandistrogene moxeparvovec-rokl), an adeno-associated virus vector-based gene therapy.
The two reported deaths in non-ambulatory DMD patients appear to be related to treatment with Elevidys. Reports were received from clinical trial and postmarketing data.
Also Read: <a href="https://www.benzinga.com/news/fda/25/06/45945282/sarepta-therapeutics-stock-plummets-over-40-on-second-fatal-case-linked-to-its-gene-therapy">Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy</a>
In these two cases, the patients presented with elevated transaminases and were hospitalized less than two months after treatment with Elevidys.
On Wednesday, HC Wainwright reiterated its Sell rating for Sarepta, maintaining a <a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/06/46034962/analyst-downgrades-sarepta-as-elevidys-safety-clouds-future-demand">price forecast of $10</a>. Analyst Mitchell Kapoor stated his belief that &#8220;it is highly likely that the FDA will at least require updated language to the USPI to denote the risk of liver failure or death.&#8221;
The analyst says the worst-case scenario for Sarepta would be if the FDA ultimately required the company to withdraw Elevidys from the U.S. market.
Kapoor underscored a critical risk for Sarepta, stating, &#8220;If Elevidys were to be withdrawn, we see little intrinsic value remaining in the company.&#8221; 
Kapoor further highlighted the FDA as a potential headwind, noting that Center for Biologics Evaluation and Research (CBER) head Vinay Prasad has previously voiced strong disapproval of Peter Marks&#8217; initial approval of Elevidys. 
This established skepticism from Dr. Prasad, even prior to the recent reports of liver failure deaths, suggests a likely reluctance to support Sarepta&#8217;s continued marketing of Elevidys.
For a broader perspective on Sarepta&#8217;s outlook, explore how other <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">analysts view the stock</a>.
Price Action: SRPT stock is trading lower by 9.96% to $17.09 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/legal/25/06/46098969/bristol-myers-faces-scrutiny-for-allegedly-rigging-market-on-2b-cancer-drug" target="_blank" rel="noreferrer noopener">Bristol Myers Faces Scrutiny For Allegedly Rigging Market On $2B Cancer Drug</a></li>
</ul>
Photo by Tada Images via Shutterstock

Analyst Color

Biotech

News

Health Care

Price Target

Reiteration

Analyst Ratings

Movers

Trading Ideas

General

SRPT

Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny

WIIM

Sarepta Therapeutics shares are trading lower after HC Wainwright & Co. downgraded the stock from Neutral to Sell and cut its price target on the stock from $40 to $10.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>HC Wainwright &amp; Co. analyst Mitchell Kapoor downgraded Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Neutral to Sell and lowered the price target from $40 to $10. Sarepta Therapeutics shares closed at $18.98 on Tuesday. <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BTIG analyst Gregory Lewis downgraded the rating for NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) from Buy to Neutral. NuScale Power shares closed at $43.24 on Tuesday. <a href="https://www.benzinga.com/quote/SMR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Carly Davenport downgraded WEC Energy Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) from Neutral to Sell and lowered the price target from $106 to $100. WEC Energy shares closed at $105.36 on Tuesday. <a href="https://www.benzinga.com/quote/WEC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Macquarie analyst James Hong downgraded the rating for Honda Motor Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) from Outperform to Neutral. Honda Motor shares closed at $28.88 on Tuesday. <a href="https://www.benzinga.com/quote/HMC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Julien Roch downgraded Omnicom Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>) from Overweight to Equal-Weight and lowered the price target from $105 to $80. Omnicom Group shares closed at $72.48 on Tuesday. <a href="https://www.benzinga.com/quote/OMC/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SRPT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/srpt/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="635" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25101702/image-386-1024x635.png" alt="" class="wp-image-961722" style="width:653px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25101702/image-386-1024x635.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25101702/image-386-300x186.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25101702/image-386-768x477.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25101702/image-386.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46072226/top-3-real-estate-stocks-you-may-want-to-dump-in-june">Top 3 Real Estate Stocks You May Want To Dump In June</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Markets

This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday

In the preceding three months, 38 analysts have released ratings for Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">16</td>
<td align="right">14</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $72.34, a high estimate of $183.00, and a low estimate of $10.00. Highlighting a 37.16% decrease, the current average has fallen from the previous average price target of $115.11. 
<img src="https://www.benzinga.com/files/images/story/2025/1750852858_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Sarepta Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Sell</td>
<td>$10.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Uy Ear</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$25.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$29.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Andrew Tsai</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$54.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$70.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Sell</td>
<td>$10.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>Maintains</td>
<td>Sector Outperform</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$89.00</td>
<td>$209.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$58.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$98.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$123.00</td>
<td>$184.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$113.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$125.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$182.00</td>
<td>$196.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$115.00</td>
<td>-</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$183.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$87.00</td>
<td>$161.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sarepta Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sarepta Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Sarepta Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Sarepta Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SRPT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sarepta Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Sarepta Therapeutics: A Closer Look</h2>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
<h3>Sarepta Therapeutics: A Financial Overview</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Positive Revenue Trend: Examining Sarepta Therapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 80.15% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Sarepta Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -60.08%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Sarepta Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -33.52%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Sarepta Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -12.05%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 1.18, Sarepta Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Sarepta Therapeutics: Insights From 38 Financial Analysts

HC Wainwright &amp; Co. analyst Mitchell Kapoor downgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Neutral to Sell and lowers the price target from $40 to $10.

HC Wainwright & Co. Downgrades Sarepta Therapeutics to Sell, Lowers Price Target to $10

Reuters Reports FDA Investigating Deaths Due To Acute Liver Failure In Non-Ambulatory Duchenne Muscular Dystrophy Patients Following Elevidys; Says Two Reported Deaths In Non-Ambulatory DMD Patients Appear To Be Related To Treatment With Elevidys

Earlier this week, Sarepta Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) provided a safety update regarding Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy, and steps the company is taking to strengthen the safety profile in <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">non-ambulatory patients</a>.
These steps follow a second reported case of acute liver failure (ALF), <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/45945282/sarepta-therapeutics-stock-plummets-over-40-on-second-fatal-case-linked-to-its-gene-therapy" rel="noreferrer noopener">resulting in death</a>.
William Blair says, &#8220;One key factor leading to investor hesitancy is the lack of clarity over how many additional non-ambulatory patients have been treated and are still within the time frame to potentially develop acute liver failure, creating uncertainty over the risk of another fatality in the near term.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45261806/sarepta-therapeutics-stock-sinks-on-gloomy-forecast-analysts-cut-price-forecasts" rel="noreferrer noopener">Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up</a>
On Friday, analyst Sami Corwin downgraded Sarepta from <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings" target="_blank" rel="noreferrer noopener">Outperform to Market Perform</a>.
Corwin said, &#8220;In addition, significant penetration of the non-ambulatory population was a key consideration of prior peak revenue estimates, and it is unlikely that penetration will be as robust in this subgroup in the future, in our opinion.&#8221;
Peak revenue estimates might decline further if other AAV gene therapies for Duchenne muscular dystrophy hit the market as soon as 2027. Notably, early clinical data suggests that some of these therapies — such as Solid Biosciences Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) SGT-003 — could have a safer profile, with fewer signs of liver-related side effects.
&#8220;While we continue to think that there will be strong interest among commercial ambulatory patients in Elevidys and that a higher share price is therefore justified based on our sum-of-the parts analysis, at this time, we think the reduction in peak revenue opportunity and growing number of uncertain variables will be a deterrent for investors,&#8221; William Blair wrote in the investor note on Friday.
SRPT Price Action: Sarepta Therapeutics stock is down 3.18% at $20.11 at publication on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/02/43790793/solid-biosciences-stock-surges-on-upbeat-duchenne-muscular-dystrophy-gene-therapy-data" target="_blank" rel="noreferrer noopener">Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data</a></li>
</ul>
Photo: Monkey Business Photos via Shutterstock

SLDB

Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand

Oppenheimer analyst Hartaj Singh maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Outperform and lowers the price target from $123 to $45.

Oppenheimer Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $45

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>William Blair analyst Sami Corwin downgraded Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Outperform to Market Perform. Sarepta Therapeutics shares closed at $20.77 on Wednesday. <a href="https://www.benzinga.com/quote/srpt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Mikhail Goberman downgraded the rating for Guild Holdings Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHLD#NYSE">GHLD</a>) from Market Outperform to Market Perform. Guild Holdings shares closed at $19.72 on Wednesday. <a href="https://www.benzinga.com/quote/GHLD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer analyst Noah Kaye downgraded the rating for Johnson Controls International plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) from Outperform to Perform. Johnson Controls shares closed at $103.48 on Wednesday. <a href="https://www.benzinga.com/quote/GHLD/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/JCI/analyst-ratings">how </a><a href="https://www.benzinga.com/quote/GHLD/analyst-ratings">other analysts view this stock</a>.</li>
</ul>
Considering buying SRPT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/SRPT/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="615" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20104338/image-313-1024x615.png" alt="" class="wp-image-956269" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20104338/image-313-1024x615.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20104338/image-313-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20104338/image-313-768x461.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20104338/image-313.png 1133w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/46024423/how-to-earn-500-a-month-from-commercial-metals-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Commercial Metals Stock Ahead Of Q3 Earnings</a> </li>
</ul>
Photo via Shutterstock

GHLD

This Sarepta Therapeutics Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday

William Blair analyst Sami Corwin downgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Outperform to Market Perform.

William Blair Downgrades Sarepta Therapeutics to Market Perform

Mizuho analyst Uy Ear maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Outperform and lowers the price target from $85 to $40.

Mizuho Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $40

Deutsche Bank analyst David Hoang maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Hold and lowers the price target from $50 to $25.

Deutsche Bank Maintains Hold on Sarepta Therapeutics, Lowers Price Target to $25

Goldman Sachs analyst Salveen Richter downgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Buy to Neutral and announces $29 price target.

Goldman Sachs Downgrades Sarepta Therapeutics to Neutral, Announces $29 Price Target

Morgan Stanley analyst Matthew Harrison downgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Overweight to Equal-Weight and lowers the price target from $113 to $40.

Morgan Stanley Downgrades Sarepta Therapeutics to Equal-Weight, Lowers Price Target to $40

Baird analyst Brian Skorney maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Outperform and lowers the price target from $60 to $30.

Baird Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $30

Wells Fargo analyst Yanan Zhu maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight and lowers the price target from $100 to $75.

Wells Fargo Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $75

Wolfe Research analyst Andy Chen initiates coverage on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Peer Perform rating.

Initiation

Wolfe Research Initiates Coverage On Sarepta Therapeutics with Peer Perform Rating

U.S. stock futures were trading lower on Tuesday following Monday&#8217;s advance. Futures of major benchmark indices were lower in premarket.
President Donald Trump called on <a href="https://www.benzinga.com/news/events/25/06/45964856/trump-asks-everyone-to-immediately-evacuate-tehran-odds-of-us-striking-iran-spike-on-crypto-betting-platform">Iranians to leave Tehran</a>, pointing to the government&#8217;s refusal to accept a deal aimed at limiting nuclear weapons development, amid ongoing attacks between Israel and Iran that marked the fifth consecutive day on Tuesday.
At the G7 summit in Canada, world leaders urged a reduction in tensions during the most severe clash ever between these regional adversaries, labeling Iran as a source of instability and insisting it must never acquire nuclear weapons, while also recognizing Israel&#8217;s right to self-defense.
Trump took to Truth Social on Monday to clarify his abrupt departure from the G7 Summit in Canada. He refuted Macron's claim that he was returning to Washington to negotiate a ceasefire between Israel and Iran. "He has no idea why I am now on my way to Washington, but it certainly has nothing to do with a Cease Fire. Much bigger than that," Trump wrote.
Trump had previously urged citizens of Tehran, Iran's capital, to evacuate immediately, indicating a potential U.S. involvement in the conflict.
Meanwhile, President Trump, while on Air Force One returning from the G-7 summit, told reporters he is seeking <a href="https://www.benzinga.com/markets/equities/25/06/45968002/trump-says-israel-iran-ceasefire-not-on-the-table-left-g7-early-for-a-much-bigger-reason-spy-qqq">&#8220;a real end&#8221; to Iran&#8217;s nuclear issue</a>, with Tehran giving it up &#8220;entirely.&#8221;
The 10-year Treasury bond yielded 4.43% and the two-year bond was at 3.96%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 99.9% likelihood of the Federal Reserve keeping the current interest rates unchanged in its June meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.59%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.54%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.46%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.94%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Tuesday. The SPY was down 0.54% at $599.42, while the QQQ declined 0.58% to $531.18, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Communication services, information technology, and consumer discretionary stocks recorded the biggest gains on Monday, leading most sectors on the S&amp;P 500 to close on a positive note, while utilities and health care stocks bucked the overall market trend, ending the session lower.
Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares surged over 35% on Monday following Supernus Pharmaceuticals&#8217; agreement to acquire the company.
Conversely, shares of Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) dropped more than 42% after the company halted ELEVIDYS shipments and paused the ENVISION trial due to a second fatal liver failure in non-ambulatory Duchenne patients.
On the economic front, the New York Empire State Manufacturing Index fell to a reading of -16 in June, down from May's figure of -9.2 and below market expectations of -5.5.
The Dow Jones index ended 317 points or 0.75% higher at 42,515.09, whereas the S&amp;P 500 index rose 0.94% to 6,033.11. Nasdaq Composite advanced 1.52% to 19,701.21, and the small-cap gauge, Russell 2000, gained 1.12% to end at 2,124.13.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>1.52%</td>
<td>19,701.21</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.94%</td>
<td>6,033.11</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.75%</td>
<td>42,515.09</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.12%</td>
<td>2,124.13</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Despite the dominating geopolitical headlines, a senior economist at WisdomTree, Jeremy Siegel, told investors that they need to focus on the more meaningful development: &#8220;the continued softening of inflation data.&#8221;
&#8220;Both CPI and PPI came in on the low side, confirming the disinflationary trend that's been evident. These price increases have not yet fully worked their way into the data and are likely to show up over the next couple of months. Even so, the underlying trend is down (excluding tariff impacts coming up). My view remains firm: ex-tariffs, inflation is cooling, and the Fed should begin easing policy,&#8221; he said.
He said that he remains &#8220;optimistic&#8221; about the stock market. &#8220;Markets have shown impressive resilience, inflation is heading in the right direction, and the Fed will ultimately come along. Stay focused on fundamentals and avoid getting whipsawed by noise,&#8221; he added.
Meanwhile, Jeff Buchbinder, the chief equity strategist at LPL Financial explained that there are several key questions to answer before we know how stocks will handle this geopolitical shock, including how much of Iran's energy infrastructure will be impaired and for how long, whether Iran's nuclear capabilities will be completely wiped out, and whether the current regime will remain in power.
For those surprised that the U.S. stock market held up well on Monday, Buchbinder argued that it was a combination of several factors:
<ul class="wp-block-list">
<li>The likelihood of regime change in Iran and a resulting "peace dividend",</li>
<li>U.S. energy independence,</li>
<li>Israel's interest in limiting the suffering of Iranian civilians (which could mean limited disruption to oil production facilities), and</li>
<li>Both players have limited resources and an interest in keeping the conflict contained.</li>
</ul>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul class="wp-block-list">
<li>May&#8217;s U.S. retail sales and import price index will be out by 8:30 a.m. ET.</li>
<li>May&#8217;s industrial production and capacity utilization will be announced by 9:15 a.m. ET.</li>
<li>April Business inventories data and June&#8217;s home builder confidence index data will be released at 10:00 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) was up 0.65% in premarket on Tuesday as analysts expect it to report quarterly earnings of $2.31 per share on revenue of $7.06 billion, before the opening bell.</li>
<li>John Wiley &amp; Sons Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLY#NYSE">WLY</a>) advanced 2.03% ahead of its earnings, which are supposed to be released before the opening bell. Analysts expect earnings of $1.27 per share on revenue of $434.90 million.</li>
<li>La-Z-Boy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LZB#NYSE">LZB</a>) declined 0.077% as analysts expect it to report quarterly earnings of 93 cents per share on revenue of $557.44 million, after the closing bell.</li>
<li>Globus Maritime Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBS#NASDAQ">GLBS</a>) dropped 3.91% after posting downbeat results for the first quarter on Monday. The company reported a quarterly loss of 7 cents per share, compared to market estimates of a loss of 3 cents per share.</li>
<li>Lennar Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) was up 2.70% after reporting mixed results for the second quarter after Monday's closing bell.</li>
<li>Digital Turbine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) jumped 6.86% after it reported quarterly earnings of 10 cents per share, which beat the analyst consensus estimate of four cents.</li>
<li>High Tide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) edged 2.67% higher after it reported second-quarter revenue of $96.94 million versus estimates of $96.73 million, up 11% year-over-year.</li>
<li>Redwire Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) plunged 9.14% after it announced a $200 million registered public offering of common stock.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 1.48% to hover around $71.29 per barrel.
Gold Spot US Dollar fell 0.18% to hover around $3,379.21 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was higher by 0.19% at the 98.1870 level.
Asian markets ended mixed on Tuesday as South Korea's Kospi and Japan's Nikkei 225 indices rose. While China&#8217;s CSI 300, Hong Kong's Hang Seng, Australia's ASX 200, and India's S&amp;P BSE Sensex indices declined. European markets were lower in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45967469/us-equity-funds-are-raking-in-billions-these-are-the-ones-beating-trumps-tariff-shock-in-2025">US Equity Funds Are Raking In Billions—These Are The Ones Beating Trump&#8217;s Tariff Shock in 2025</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

APPS

GLBS

HITI

SAGE

US Stock Futures Tumble After Trump Threatens 'Real End' To Iran's Nuclear Problem: '…Avoid Getting Whipsawed By Noise,' Says Expert

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Monday.
U.S. stocks settled higher on Monday, with the Dow Jones index gaining more than 300 points during the session after Iran signaled it wants to de-escalate tensions with Israel and return to negotiations, easing geopolitical jitters that had rattled investors and sent oil prices surging last week.
Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares surged over 35% on Monday after Supernus Pharmaceuticals agreed to acquire the company. Shares of Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) dipped more than 42% after the company suspended ELEVIDYS shipments and paused the ENVISION trial following a second fatal liver failure in non-ambulatory Duchenne patients.
On the economic front, the New York Empire State Manufacturing Index dipped to a reading of -16 in June compared to May&#8217;s reading of -9.2, and also down from market estimates of -5.5.
Most sectors on the S&amp;P 500 closed on a positive note, with communication services, information technology and consumer discretionary stocks recording the biggest gains on Monday. However, utilities and health care stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 317 points to 42,515.09 on Monday. The S&amp;P 500 gained 0.94% to 6,033.11, while the Nasdaq Composite climbed 1.52% to 19,701.21 during Monday's session.
Investors are awaiting earnings results from Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>), John Wiley &amp; Sons Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLY#NYSE">WLY</a>) and La-Z-Boy Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LZB#NYSE">LZB</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 62, the index remained in the &#8220;Greed&#8221; zone on Monday, versus a prior reading of 60.3.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45948533/top-2-financial-stocks-that-may-plunge-in-q2">Top 2 Financial Stocks That May Plunge in Q2</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone

Jefferies analyst Andrew Tsai maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Buy and lowers the price target from $125 to $54.

Jefferies Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $54

Press Releases

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. is being Investigated for Securities Fraud after Second Elevidys Death; Investors with Losses are Notified to Contact BFA Law

Comments

Sarepta Therapeutics

空売り

Sarepta Therapeutics (NASDAQ:SRPT) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル